• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

New Alzheimer’s Drug Slows Decline, But Its Trial Is Linked To Deaths

December 2, 2022 by Deborah Bloomfield

The experimental drug lecanemab has been shown to slow cognitive decline in people with early Alzheimer’s disease. While the long-awaited trial has been heralded as a “historic moment for dementia research”, the death of some participants in the research has sparked concerns about the risk for some people.

Lecanemab is a monoclonal antibody that works by actively removing sticky gunk, known as amyloid-beta, that builds up in the brains of people with Alzheimer’s. During an 18-month trial of almost 1,800 people with early Alzheimer’s, they found that the drug slowed cognitive and functional decline by 27 percent.

Advertisement

Biogen and Eisai, the makers of the drug, stoked some excitement about the trial in September, but the full data has now been published in a prestigious peer-reviewed journal. 

“This is the first time a drug has been shown to both reduce the disease in the brain and slow memory decline in clinical trials”, Dr Susan Kohlhaas, Director of Research at Alzheimer’s Research UK, said in a statement.

“Although the benefits were small and came with significant side effects, it marks the arrival of a treatment that can slow the course of Alzheimer’s disease. With all this excitement, there are still many questions and challenges we need to address”, continued Dr Kohlhaas.

Advertisement

The promising results have been somewhat marred by a number of deaths in trials and there are some worries about whether the drug is safe for some patients, especially those taking blood thinners.

At least two people in the trial died after taking the drug, according to media reports by STAT News and Science.  One of these fatalities was a 65-year-old woman who died from a massive brain hemorrhage that some researchers link to the drug. The other was a man in his late 80s who was taking a blood thinner for a heart condition. 

Paired with these two deaths, the data from the trial shows that six lecanemab-treated patients suffered from strokes. 

Advertisement

Biogen and Eisai deny that the trials show the drug is risky. They claim that neither of the deaths was directly related to treatment and the number of deaths in the placebo group and in the lecanemab-treated group was similar. 

Nevertheless, the potentially related deaths will raise some eyebrows and could impact decisions about how widely the drug should be prescribed if – and it’s still an if – it is eventually approved by regulators.

“Recent reports of two deaths from strokes, attributed to a side-effect of the drug, are concerning. The data published today indicate that six lecanemab-treated patients suffered strokes during the trial compared with two in the placebo group. Treatment, therefore, does carry risks, and in some rare cases this can be severe or life-threatening,” commented Rob Howard, Professor of Old Age Psychiatry at UCL, who was not involved in the research.

Advertisement

“I suspect that the lack of demonstrable clinical effectiveness will mean that lecanemab will not be taken up widely within healthcare systems around the World, although there will always be those whose heart rules their head”, added Professor Howard. 

The results of the clinical trial were published on November 29 in the New England Journal of Medicine.

Deborah Bloomfield
Deborah Bloomfield

Related posts:

  1. Afghan journalists beaten in Taliban detention, editor says
  2. Syria sees spike in COVID-19 cases as fears grow of new wave
  3. U.S. Senate confirms deputy trade representative
  4. Improving startup results through female leadership

Source Link: New Alzheimer's Drug Slows Decline, But Its Trial Is Linked To Deaths

Filed Under: News

Primary Sidebar

  • Have You Seen This Snake? Florida Wants Your Help Finding Rare Species Seen Once In 50 Years
  • Plague Confirmed In Lake Tahoe Area For First Time In 5 Years, California Officials Say
  • Supergiant Star Spotted Blowing Milky Way’s Largest Bubble Of Its Kind, Surprising Astronomers
  • Game Theory Promised To Explain Human Decisions. Did It?
  • Genes, Hormones, And Hairstyling – Here Are Some Causes Of Hair Loss You Might Not Have Heard Of
  • Answer To 30-Year-Old Mystery Code Embedded In The Kryptos CIA Sculpture To Be Sold At Auction
  • Merry Mice: Human Brain Cells Transplanted Into Mice Reduce Anxiety And Depression
  • Asteroid-Bound NASA Mission Snaps Earth-Moon Portrait From 290 Million Kilometers Away
  • Forget State Mammals – Some States Have Official Dinosaurs, And They’re Awesome
  • Female Jumping Spiders Of Two Species Prefer The Sexy Red Males Of One, Leading To Hybridization
  • Why Is It So Difficult To Find New Moons In The Solar System?
  • New “Oxygen-Breathing” Crystal Could Recharge Fuel Cells And More
  • Some Gut Bacteria Cause Insomnia While Others Protect Against It, 400,000-Person Study Argues
  • Neanderthals And Homo Sapiens Got It On 100,000 Years Earlier Than We Thought
  • “Womb Of The Universe”: Native American Tribal Elders Help Archaeologists Decipher Ancient Rock Art In Missouri Cave
  • 16,000-Year-Old Paintings Suggest Prehistoric Humans Risked Their Lives To Enter “Shaman Training Cave”
  • Final Gasps Of A Dying Star Seen Through A Record-Breaking 130 Years Of Data
  • COVID-19 “Vaccine Alternative” Injection Could Be On Fast-Track To Approval From FDA
  • New Jersey Officials Investigate Possible First Locally Acquired Malaria Case Since 1991
  • First-of-Its-Kind Bright Orange Nurse Shark Recorded Off Costa Rica Makes History
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version